Biotechnology News and Research

RSS

Turning microRNAs into novel drugs

Researchers around the globe are working on turning microRNAs, over 5,000 of which already have been identified, into novel drugs for a wide range of applications, reports Genetic Engineering & Biotechnology News (GEN). These noncoding single-stranded RNAs act through binding to complementary mRNA sequences, thus preventing their translation into protein or accelerating mRNA breakdown, according to the March 15 issue of GEN.

20 Mar 2010

Innovative tissue damage preventing cardiac scaffold awarded Rappaport Prize for biomedical research

Prof. Smadar Cohen, head of the University's Avram and Stella Goldstein-Goren Department of Biotechnology Engineering, has been awarded the prestigious Rappaport Prize for Excellence in Biomedical Research, an award totaling $100,000. The prize, given by Israel's Rappaport Foundation, is presented annually to a researcher whose research has either significantly advanced or has the potential to significantly advance any medical or biomedical field.

20 Mar 2010

Pressure BioSciences announces presentations on advantages of PCT

Pressure BioSciences, Inc. today announced that five presentations on the advantages of pressure cycling technology (PCT) in the preparation, processing, identification, and quantification of proteins were made at last week's annual meeting of US HUPO (Human Proteomics Organization) in Denver, Colorado.

From Thermo Fisher Scientific Inc. 19 Mar 2010

Teva Pharmaceutical Industries receives right to market generic version of Schering’s Temodar

Teva Pharmaceutical Industries Ltd. announced today that the parties to the patent litigation regarding Barr’s U.S. generic version of Schering’s Temodar® have entered into an agreement pending resolution of Schering’s appeal to the Federal Circuit of the U.S. District Court’s decision holding the ‘291 Patent unenforceable.

19 Mar 2010

Collaborative project yields aqueous solubility data for over 20,000 compounds in NIH Molecular Library

A collaborative project between Sanford-Burnham Medical Research Institute at Lake Nona and Analiza, Inc. has yielded aqueous solubility data for over 20,000 compounds in the NIH Molecular Library within the first 90 days of screening and characterization.

19 Mar 2010

CHMP issues positive opinion recommending approval of Tarceva as monotherapy for NSCLC

OSI Pharmaceuticals, Inc. announced today that its international partner for Tarceva® (erlotinib), Roche, informed OSI that the European Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval of Tarceva as monotherapy for maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with stable disease following four cycles of standard platinum-based first-line chemotherapy.

19 Mar 2010

PhRMA President honors Ron and Raychel Bartek for driving awareness of Friedreich's ataxia

Pharmaceutical Research and Manufacturers of America President and CEO Billy Tauzin today honored Ron and Raychel Bartek for their dedicated work driving awareness of Friedreich's ataxia, a debilitating, life-threatening, rare disease.

19 Mar 2010

Advaxis publishes new findings on Listeria-derived ActA anti-cancer component

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has published new research findings on ActA as a potential, anti-cancer component and a new complement to the Company’s evolving proprietary Listeria technology platform.

19 Mar 2010

W. R. Grace earns GMP certification

W. R. Grace & Co.has earned Good Manufacturing Practices certification of its facility in Baltimore, Maryland. The certification encompasses Grace’s Quality Management System that includes the standards, procedures and manufacturing operations used by the company in the production of pharmaceutical grade silica (commonly marketed by Grace under the SYLOID® brand name).

19 Mar 2010

Norgen Biotek launches over 30 new kits for NA based diagnostics

Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on advancing powerful tools for nucleic acids (NA) and protein purification, today announced the launch of over 30 new kits for nucleic-acid based diagnostics. Norgen makes best-in-class kits for nucleic acid and protein sample preparation, and has recognized that high quality sample preparation is the key to high quality diagnostics.

19 Mar 2010

Phase 1B clinical study initiated to evaluate safety and efficacy of PMX-60056

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 1B clinical study to evaluate the safety and efficacy of PMX-60056 in reversing the anticoagulant activity of low molecule weight heparin (LMWH).

19 Mar 2010

Three scientists receive 2010 Discoverers Award for developing new class of HIV drug

Three scientists who led the 11-year quest to develop a groundbreaking HIV drug today received the 2010 Discoverers Award -- the highest honor given to scientists by the Pharmaceutical Research and Manufacturers of America. The honorees are Tony Wood, Ph.D., Elna van der Ryst, M.D., Ph.D. and Manos Perros, Ph.D.

19 Mar 2010

Proteacel acquires exclusive rights to PORE technology from Moffitt Cancer Center

Moffitt Cancer Center and Proteacel LLC announced today that they have entered a licensing agreement under which Proteacel has acquired the exclusive rights to the PORE™ technology for delivery of genes into cells.

18 Mar 2010

ISCO commences second phase of testing RPE derived from parthenogenetic stem cells

International Stem Cell Corporation, announced today that ISCO's Research and Therapeutic Development Group, together with a group of scientists from the University of California, Irvine (UCI), is starting a second phase of essential pre-clinical experiments to test retinal pigment epithelium derived from parthenogenetic stem cells. Follow on pre-clinical experiments will be conducted to rescue vision in disease models.

18 Mar 2010

SciQuest introduces PBA methodology for Life Sciences to improve procurement operations

SciQuest, Inc., the global software leader empowering enterprises to realize the potential of strategic procurement, today unveiled a comprehensive methodology that provides leaders with a framework to build and execute a sound business plan to improve existing procurement processes, systems and protocol. This new service, the Procurement Business Assessment (PBA), enables life sciences companies to quickly uncover cost-saving opportunities in their procurement operations.

18 Mar 2010

Teva Pharmaceutical Industries to acquire ratiopharm for €3.625 billion

Teva Pharmaceutical Industries Ltd. announced today that it has entered into a definitive agreement to acquire ratiopharm, Germany’s second largest generics producer and the sixth largest generic drug company worldwide, for an enterprise value of €3.625 billion. The transaction is subject to certain conditions including relevant regulatory approvals. On a pro forma basis, the combined company would have had 2009 revenues of $16.2 billion. Teva expects to complete the transaction by year-end 2010.

18 Mar 2010

APCER Pharma to manage pharmacovigilance strategies for six global pharmaceutical companies

APCER Pharma announced that in the past three months it has further expanded its customer base and operations. APCER is a leading global provider of comprehensive drug safety, regulatory services and risk management programs for pharmaceutical, biotechnology, medical device and consumer products companies.

18 Mar 2010

ISR Reports launches new and substantial research report: Late Phase Market Dynamics

Industry Standard Research today announced the launch of a new and substantial research report titled Late Phase Market Dynamics. This report presents data and analysis from 149 interviews with decision makers from 95 unique pharmaceutical and biotechnology companies around the world.

18 Mar 2010

Bavarian Nordic completes last step to support use of IMVAMUNE, receives FDA notification

Bavarian Nordic A/S announced today that it has received notification that the U.S. Food and Drug Administration (FDA) has accepted all the actions taken by the company to address the observations made during the inspection of the manufacturing facilities in 2009. This was the last step along with the clinical and preclinical data that will be used to potentially support the use of IMVAMUNE® following a declared emergency.

18 Mar 2010

NexACT technology demonstrates ability to deliver Taxol subcutaneously

NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully demonstrated the ability of the NexACT technology to deliver insulin and other large molecule drugs such as Taxol subcutaneously, in a depot-like fashion (or slow release) over a 24 hour period from a single injection.

18 Mar 2010

Biotechnology News and Research

Turning microRNAs into novel drugs

Innovative tissue damage preventing cardiac scaffold awarded Rappaport Prize for biomedical research

Pressure BioSciences announces presentations on advantages of PCT

Teva Pharmaceutical Industries receives right to market generic version of Schering’s Temodar

Collaborative project yields aqueous solubility data for over 20,000 compounds in NIH Molecular Library

CHMP issues positive opinion recommending approval of Tarceva as monotherapy for NSCLC

PhRMA President honors Ron and Raychel Bartek for driving awareness of Friedreich's ataxia

Advaxis publishes new findings on Listeria-derived ActA anti-cancer component

W. R. Grace earns GMP certification

Norgen Biotek launches over 30 new kits for NA based diagnostics

Phase 1B clinical study initiated to evaluate safety and efficacy of PMX-60056

Three scientists receive 2010 Discoverers Award for developing new class of HIV drug

Proteacel acquires exclusive rights to PORE technology from Moffitt Cancer Center

ISCO commences second phase of testing RPE derived from parthenogenetic stem cells

SciQuest introduces PBA methodology for Life Sciences to improve procurement operations

Teva Pharmaceutical Industries to acquire ratiopharm for €3.625 billion

APCER Pharma to manage pharmacovigilance strategies for six global pharmaceutical companies

ISR Reports launches new and substantial research report: Late Phase Market Dynamics

Bavarian Nordic completes last step to support use of IMVAMUNE, receives FDA notification

NexACT technology demonstrates ability to deliver Taxol subcutaneously

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News